Objective: De novo CD5-positive (CD5+) diffuse large B-cell lymphoma (DLBCL) has different clinical characteristics compared with CD5-negative (CD5-) DLBCL. However, few studies have been reported in Chinese cohorts. We investigated the clinical features and prognosis of patients with CD5+ DLBCL and summarized the related literature.
Methods: Data from 245 patients with newly diagnosed DLBCL were retrospectively assessed.
Results: Thirty-one and 214 patients were diagnosed with CD5+ DLBCL or CD5- DLBCL, respectively. In the CD5+ DLBCL group, there were significantly higher proportions of patients with older age (≥60 years), International Prognostic Index (IPI) ≥3, Eastern Cooperative Oncology Group (ECOG) scores ≥ 2, bone marrow involvement, positive B-cell lymphoma 2 expression, and positive MYC expression. Survival analysis showed that CD5+ DLBCL had a markedly poorer 2-year progression-free survival than CD5- DLBCL (18.2% vs. 56.2%). Univariate analysis indicated that age ≥60 years, ECOG score ≥ 2, IPI ≥ 3, B symptoms, and no rituximab-based treatment were poor predictive factors for overall survival (OS). Multivariate analysis revealed that B symptoms and no rituximab-based treatment, but not positive CD5 expression, were independent factors for OS.
Conclusions: Patients with CD5+ DLBCL had heterogeneous clinical characteristics and poor survival. The development of more targeted and effective therapies is needed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483961 | PMC |
| http://dx.doi.org/10.1177/03000605221110075 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary large B-cell lymphoma of the central nervous system: A reappraisal of CD5-positive cases based on clinical, pathological, and molecular evaluation.
Pathol Int
December 2024
Department of Pathology and Laboratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
CD5 expression is seen in 5%-10% of de novo diffuse large B-cell lymphomas (DLBCLs). Primary large B-cell lymphoma of the central nervous system (PCNS-LBCL) also exhibits CD5 expression in a minority of cases, however, clinicopathological and molecular features remain largely unclarified. Here we present the clinical, molecular, and pathological features of 11 CD5-positive () PCNS-LBCL cases, occupying 6.
View Article and Find Full Text PDFErythema Nodosum Secondary to CD5-Positive Diffuse Large B-Cell Lymphoma as a Paraneoplastic Symptom: A Case Report.
Case Rep Oncol
September 2024
Department of Internal Medicine, Fukuyama City Hospital, Fukuyama, Japan.
Introduction: Erythema nodosum (EN) is the most common form of panniculitis. EN can be idiopathic or secondary to an underlying systemic disease, infection, drug use, or tumor. CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) is a relapsed and refractory lymphoma, and further understanding of its pathology is required.
View Article and Find Full Text PDFTonsillar Diffuse Large B-Cell Lymphoma of Non-Germinal Center Type With Cluster of Differentiation 5 Positive in a Pediatric Girl.
J Med Cases
November 2024
Collage of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
Lymphoma is a common malignancy in children. It is the second most common malignancy in children older than 1 year of age. Most extranodal non-Hodgkin lymphoma (NHL) in the head and neck is usually caused by diffuse large B-cell lymphoma (DLBCL), but pediatric DLBCL with cluster of differentiation (CD)5 expression is rarely discussed in the literature.
View Article and Find Full Text PDFRecent advances in CD5 diffuse large B-cell lymphoma.
Ann Hematol
November 2024
Department of Hematology, Lanzhou University Second Hospital, Lanzhou, Gansu, 730030, China.
Article Synopsis
- Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin's lymphoma, with a rare subset known as CD5 DLBCL, affecting about 5-10% of patients and often presenting in older females with more severe disease symptoms.
- CD5 DLBCL patients tend to have poorer prognostic factors, such as higher levels of lactate dehydrogenase and advanced disease with increased risks of central nervous system relapse and bone marrow involvement.
- Traditional treatments like R-CHOP are less effective for CD5 DLBCL, prompting interest in newer therapies, including BTK inhibitors and immunotherapy, though further research is needed to ascertain the best treatment approaches.
[Clinical Analysis of PD-1 Inhibitor Combined with Lenalidomide in Treatment of Relapsed CD5 Diffuse Large B-Cell Lymphoma].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
August 2024
Department of Hematology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian Province, China.
Article Synopsis
- The study focused on a patient with relapsed CD5 diffuse large B-cell lymphoma (DLBCL), analyzing their clinical features and treatment results.
- After initially achieving complete remission with R-ECHOP chemotherapy, the patient relapsed but responded well to a combination of PD-1 inhibitors and lenalidomide, leading to another complete remission and reduced IL-10 levels.
- These findings suggest that the PD-1 inhibitor plus lenalidomide could be a promising new therapy for patients with relapsed CD5 DLBCL.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!